| Literature DB >> 31606272 |
Daiki Takahashi1, Jun Moriyama1, Tomoe Nakamura1, Erika Miki1, Eriko Takahashi1, Ayami Sato1, Takaaki Akaike2, Kaori Itto-Nakama1, Hirokazu Arimoto3.
Abstract
Protein silencing represents an essential tool in biomedical research. Targeted protein degradation (TPD) strategies exemplified by PROTACs are rapidly emerging as modalities in drug discovery. However, the scope of current TPD techniques is limited because many intracellular materials are not substrates of proteasomal clearance. Here, we described a novel targeted-clearance strategy (autophagy-targeting chimera [AUTAC]) that contains a degradation tag (guanine derivatives) and a warhead to provide target specificity. As expected from the substrate scope of autophagy, AUTAC degraded fragmented mitochondria as well as proteins. Mitochondria-targeted AUTAC accelerated both the removal of dysfunctional fragmented mitochondria and the biogenesis of functionally normal mitochondria in patient-derived fibroblast cells. Cytoprotective effects against acute mitochondrial injuries were also seen. Canonical autophagy is viewed as a nonselective bulk decomposition system, and none of the available autophagy-inducing agents exhibit useful cargo selectivity. With its target specificity, AUTAC provides a new modality for research on autophagy-based drugs.Entities:
Keywords: AUTAC; Down syndrome; K63-linked polyubiquitin; PROTACs; S-guanylation; autophagy; cargo-specific degrader; drug discovery; mitophagy; targeted protein degradation
Mesh:
Substances:
Year: 2019 PMID: 31606272 DOI: 10.1016/j.molcel.2019.09.009
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970